217 related articles for article (PubMed ID: 27497757)
21. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
[TBL] [Abstract][Full Text] [Related]
23. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
Tsirigotis P; Byrne M; Schmid C; Baron F; Ciceri F; Esteve J; Gorin NC; Giebel S; Mohty M; Savani BN; Nagler A
Bone Marrow Transplant; 2016 Nov; 51(11):1431-1438. PubMed ID: 27295272
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
25. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
26. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
27. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
[TBL] [Abstract][Full Text] [Related]
28. New drugs for acute myeloid leukemia inspired by genomics and when to use them.
Pollyea DA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):45-50. PubMed ID: 30504290
[TBL] [Abstract][Full Text] [Related]
29. Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.
Borate U; Absher D; Erba HP; Pasche B
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1289-97. PubMed ID: 23176617
[TBL] [Abstract][Full Text] [Related]
30. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
31. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
32. Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.
Casado P; Cutillas PR
Mol Cell Proteomics; 2023 Apr; 22(4):100517. PubMed ID: 36805445
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
[TBL] [Abstract][Full Text] [Related]
34. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Schnittger S; Schoch C; Kern W; Hiddemann W; Haferlach T
Acta Haematol; 2004; 112(1-2):68-78. PubMed ID: 15179006
[TBL] [Abstract][Full Text] [Related]
35. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
36. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Stone RM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
[TBL] [Abstract][Full Text] [Related]
37. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
Zuffa E; Franchini E; Papayannidis C; Baldazzi C; Simonetti G; Testoni N; Abbenante MC; Paolini S; Sartor C; Parisi S; Marconi G; Cattina F; Bochicchio MT; Venturi C; Ottaviani E; Cavo M; Martinelli G
Oncotarget; 2015 Oct; 6(31):31284-94. PubMed ID: 26384303
[TBL] [Abstract][Full Text] [Related]
38. Towards precision medicine for AML.
Döhner H; Wei AH; Löwenberg B
Nat Rev Clin Oncol; 2021 Sep; 18(9):577-590. PubMed ID: 34006997
[TBL] [Abstract][Full Text] [Related]
39. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
40. Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.
Wertheim GB; Hexner E; Bagg A
Mol Diagn Ther; 2012 Dec; 16(6):357-69. PubMed ID: 23184342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
